Redefining the role of biomarkers in heart failure trials: expert consensus document.
Kramer F, Sabbah HN, Januzzi JJ, Zannad F, Peter van Tintelen J, Schelbert EB, Kim RJ, Milting H, Vonk R, Neudeck B, Clark R, Witte K, Dinh W, Pieske B, Butler J, Gheorghiade M. Redefining the role of biomarkers in heart failure trials: expert consensus document. 2017 May;22(3):263-277.
Heart failure reviews
Heart failure is a growing cardiovascular disease with significant epidemiological, clinical, and societal implications and represents a high unmet need. Strong efforts are currently underway by academic and industrial researchers to develop novel treatments for heart failure. Biomarkers play an important role in patient selection and monitoring in drug trials and in clinical management. The present review gives an overview of the role of available molecular, imaging, and device-derived digital biomarkers in heart failure drug development and highlights capabilities and limitations of biomarker use in this context.
Medical Subject Headings
Biomarkers; Clinical Trials as Topic; Consensus; Diagnostic Imaging; Disease Management; Heart Failure; Humans; Patient Selection